Trade Mark Journal No.2021/053 31 December 2021
WO0000001631360 (5)
Office of origin: United States of America
Date of International Registration:9 November 2021
Date of designation in the UK:
9 November 2021

International priority date claimed: 28 October 2021
(United States of America)
(97096682)
- Class 5
- Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of thalassemia and sickle cell disease.
Vertex Pharmaceuticals Incorporated
Representative: Timothy H. Hiebert Womble Bond Dickinson (US) LLP, 470 Atlantic Ave., Boston MA 02210-2228, UNITED STATES OF AMERICA